Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults

Gupta, Sneh Lata; Mantus, Grace; Manning, Kelly; Ellis, Madison; Patel, Mit; Ciric, Caroline; Lu, Austin; Turner, Jackson S.; O’Halloran, Jane A.; Presti, Rachel; Joshi, Devyani; Ellebedy, Ali H.; Anderson, Evan J.; Rostad, Christina A.; Suthar, Mehul S.; Wrammert, Jens

doi:10.1128/jvi.00582-22

Cited by 18 publications

(20 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T478K, Q293K, Q498R and E484A contributed to an elevated transmission rate and evasion from neutralizing antibodies [ 104 ]. Due to this enhanced escaping capacity, the protection achieved with BNT162b2 and mRNA-1273 vaccines decreased to 30% after three doses, and to 47.2% in older adults [ 93 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 ]. This variant is still evolving, leading to Omicron sub-variants such as BQ, XBB and BF.7, with high capacities to avoid neutralizing antibodies elicited by the original vaccines [ 108 , 113 ].…”

Section: Advantages and Caveats Of Efficacy And Safety Of Mrna Sars-c...mentioning

confidence: 99%

mRNA Vaccines against SARS-CoV-2: Advantages and Caveats

Echaide

Chocarro

Bocanegra

et al. 2023

IJMS

View full text Add to dashboard Cite

The application of BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2 infection has constituted a determinant resource to control the COVID-19 pandemic. Since the beginning of 2021, millions of doses have been administered in several countries of North and South America and Europe. Many studies have confirmed the efficacy of these vaccines in a wide range of ages and in vulnerable groups of people against COVID-19. Nevertheless, the emergence and selection of new variants have led to a progressive decay in vaccine efficacy. Pfizer–BioNTech and Moderna developed updated bivalent vaccines—Comirnaty and Spikevax—to improve responses against the SARS-CoV-2 Omicron variants. Frequent booster doses with monovalent or bivalent mRNA vaccines, the emergence of some rare but serious adverse events and the activation of T-helper 17 responses suggest the need for improved mRNA vaccine formulations or the use of other types of vaccines. In this review, we discuss the advantages and limitations of mRNA vaccines targeting SARS-CoV-2 focusing on the most recent, related publications.

show abstract

Section: Advantages and Caveats Of Efficacy And Safety Of Mrna Sars-c...mentioning

confidence: 99%

mRNA Vaccines against SARS-CoV-2: Advantages and Caveats

Echaide

Chocarro

Bocanegra

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Children responded in a similar manner or better post-vaccination than adults. Both antibody binding and neutralizing antibody responses to SARS-CoV-2 in both very young children and adolescents exceeded those in adults [ 84 , 85 ]. Besides these two mRNA-based vaccines, Sinovac-CoronaVac and BBIBP-CorV, which are based on the inactivated virus, were approved in China for children aged 3–17 years [ 86 , 87 ].…”

Section: Status Of Vaccination In Childrenmentioning

confidence: 99%

Children’s SARS-CoV-2 Infection and Their Vaccination

et al. 2023

Self Cite

View full text Add to dashboard Cite

SARS-CoV-2, a novel coronavirus, causes respiratory tract infections and other complications in affected individuals, and has resulted in numerous deaths worldwide. The unprecedented pace of its transmission worldwide, and the resultant heavy burden on healthcare systems everywhere, prompted efforts to have effective therapeutic strategies and vaccination candidates available to the global population. While aged and immunocompromised individuals form a high-risk group for COVID-19 and have severe disease outcome, the rate of infections among children has also increased with the emergence of the Omicron variant. In addition, recent reports of threatening SARS-CoV-2-associated complications in children have brought to the forefront an urgent necessity for vaccination. In this article, we discuss the current scenario of SARS-CoV-2 infections in children with a special focus on the differences in their immune system response as compared to adults. Further, we describe the various available COVID-19 vaccines, including the recent bivalent vaccines for children, in detail, intending to increase willingness for their acceptance.

show abstract

“…The neutralizing antibody titers against live viruses of the Alpha, Beta, and Delta strains were 2 to 3, 3 to 6, and 17 to 30 times lower than those of the Wuhan-Hu-1 strain (wild-type [WT]), respectively ( 2 ). Neutralizing antibodies against the Omicron strain were minimal or undetectable when induced by mRNA vaccines, adenovirus vector vaccines, and inactivated vaccines ( 3 – 5 ). Sera from convalescing patients cannot neutralize the Omicron variant either.…”

Section: Introductionmentioning

confidence: 99%